Skip to main content
. Author manuscript; available in PMC: 2021 Sep 11.
Published in final edited form as: Circ Res. 2020 Jun 29;127(7):855–873. doi: 10.1161/CIRCRESAHA.120.316951

Figure 5. Platelet deficient of miR-223 in KD patients with CAA fails to suppress VSMC dedifferentiation.

Figure 5.

The protein expression (A) and quantification (B) of markers for differentiation (ACTA2, CNN1, TAGLN) and dedifferentiation (PCNA, OPN, PDGFRβ (HC: n=8, NCAA: n=8, CAA: n=15)) in VSMCs after incubation with platelets from HC (n=10), KD patients with CAA (n=20) and NCAA (n=20) were determined by Western blot (One-way ANOVA or Kruskall-Wallis test). VSMCs were pre-treated with agomiR-223 or antagomiR-223, followed by incubation with platelets from HC (n=9), KD patients with NCAA (n=16) or CAA (n=9). The protein expression (C) and quantification (D) of markers for differentiation (ACTA2, CNN1, TAGLN) and dedifferentiation (PCNA, OPN, PDGFRβ (HC: n=8, NCAA: n=9, CAA: n=9)) were measured by Western blot (Unpaired t test or Mann Whitney test). Abbreviations: HC, VSMCs co-cultured with platelets from HC; KD (NCAA), VSMCs co-cultured with platelets from KD patients with NCAA; KD (CAA), VSMCs co-cultured with platelets from KD patients with CAA. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.